Atezolizumab in non-squamous non-small cell lung cancer

Takaki Akamine; Gouji Toyokawa; Tetsuzo Tagawa; Takashi Seto

doi:10.21037/jtd.2018.07.92

Atezolizumab in non-squamous non-small cell lung cancer

Takaki Akamine, Gouji Toyokawa, Tetsuzo Tagawa, Takashi Seto

Chest Surgery (2)

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	S3155-S3159
Journal	Journal of Thoracic Disease
Volume	10
DOIs	https://doi.org/10.21037/jtd.2018.07.92
Publication status	Published - Sept 1 2018

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21037/jtd.2018.07.92

Cite this

@article{d9d91f2be8374f158ef44961bfff2434,

title = "Atezolizumab in non-squamous non-small cell lung cancer",

author = "Takaki Akamine and Gouji Toyokawa and Tetsuzo Tagawa and Takashi Seto",

note = "Funding Information: Yakuhin, Eisai, Merck Serono, Novartis Pharma, and Verastem; personal fees from Bristol-Myers Squibb, Kyowa Hakko Kirin, Mochida Pharmaceutical, Nippon Kayaku, Ono Pharmaceutical, Roche Singapore, Sanofi, Showa Yakuhin, Taiho Pharmaceutical and Takeda Pharmaceutical; grants and personal fees from Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Pfizer Japan, YakultHonsha, outside the submitted work. The other authors have no conflicts of interest to declare.",

year = "2018",

month = sep,

day = "1",

doi = "10.21037/jtd.2018.07.92",

language = "English",

volume = "10",

pages = "S3155--S3159",

journal = "Journal of Thoracic Disease",

issn = "2072-1439",

publisher = "Pioneer Bioscience Publishing Company (PBPC)",

}

TY - JOUR

T1 - Atezolizumab in non-squamous non-small cell lung cancer

AU - Akamine, Takaki

AU - Toyokawa, Gouji

AU - Tagawa, Tetsuzo

AU - Seto, Takashi

N1 - Funding Information: Yakuhin, Eisai, Merck Serono, Novartis Pharma, and Verastem; personal fees from Bristol-Myers Squibb, Kyowa Hakko Kirin, Mochida Pharmaceutical, Nippon Kayaku, Ono Pharmaceutical, Roche Singapore, Sanofi, Showa Yakuhin, Taiho Pharmaceutical and Takeda Pharmaceutical; grants and personal fees from Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kissei Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Pfizer Japan, YakultHonsha, outside the submitted work. The other authors have no conflicts of interest to declare.

PY - 2018/9/1

Y1 - 2018/9/1

UR - http://www.scopus.com/inward/record.url?scp=85053763722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053763722&partnerID=8YFLogxK

U2 - 10.21037/jtd.2018.07.92

DO - 10.21037/jtd.2018.07.92

M3 - Review article

AN - SCOPUS:85053763722

SN - 2072-1439

VL - 10

SP - S3155-S3159

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

ER -

Atezolizumab in non-squamous non-small cell lung cancer

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this